Celcuity (CELC) news
Recent news
Perceptive Advisors exits drug, BLTE, EVMN, NMRA in 2Q: 13F
Perceptive Advisors LLC, a biotech-focused investment firm, disclosed its second-quarter 2026 portfolio changes in a recent 13F filing. The firm exited several positions, including drugmaker Belite Bio (BLTE), Evommune (EVMN), and Neumora Therapeutics (NMRA), as part of its strategic rebalancing…
AInvest Wire · Aug 14, 2026Celcuity - Revtorpyk expected to be commercially available in U.S. in late Q3 2026
AInvest Wire · Jul 30, 2026Leerink Partners boosts Celcuity price target, increasing it to $148
Leerink Partners has revised its price target for Celcuity, raising it to $148 from a previous level, reflecting updated expectations for the company’s financial performance and market positioning. The adjustment follows a comprehensive review of Celcuity’s recent business developments and industry…
AInvest Wire · Jul 27, 2026ImportantCelcuity shares fall 22% as delayed launch of new breast cancer drug overshadows first U.S. approval
AInvest Wire · Jul 15, 2026Celcuity Inc: Jefferies cuts target price to $153 from $148
Jefferies has revised its target price for Celcuity Inc (NASDAQ: CEYC) to $153 from $148, reflecting a modest adjustment in its valuation outlook for the company. The updated target price was announced as part of the firm’s ongoing analysis of the stock, though no significant change in the overall…
AInvest Wire · Jul 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.